Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METAL study
2014-000349-59Phase 2Active
- Sponsor
- Department of Experimental and Clinical Medicine "F. Magrassi"
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of metformin and erlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Department of Experimental and Clinical Medicine "F. Magrassi". Primary endpoints: Maximum tolerated dose and Recommended Phase II dose. Started Mar 2014; status: active.
02
Drugs
metforminerlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-000349-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000349-59.